LYEL - Lyell gets FDA orphan drug designation for melanoma drug candidate
2023-11-09 17:32:29 ET
More on Lyell Immunopharma
- Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data
- JP Morgan cuts Lyell to neutral, pending data for cell therapy platform
- Seeking Alpha’s Quant Rating on Lyell Immunopharma
- Historical earnings data for Lyell Immunopharma
- Financial information for Lyell Immunopharma
For further details see:
Lyell gets FDA orphan drug designation for melanoma drug candidate